Evaluation of Serum Ages Levels in Patients With Endometriosis

Overview

Serum AGES (Advanced Glycation End Products) levels of endometriosis patients are compared with a group of healthy volunteers of the same age.

Full Title of Study: “The Serum Ages Levels in Patients With Endometriosis”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: July 20, 2021

Detailed Description

Serum AGES (Advanced Glycation End Products) levels are compared with 45 endometriosis patients and 45 healthy volunteers of the same age. The energy metabolism of the endometriosis group and its possible relationship with the endometriosis stage will be compared since AGES (Advanced Glycation End Products) gives information about the energy metabolism of the people.

Interventions

  • Other: Advanced Glycation End Products (AGEs)
    • Advanced Glycation End Products (AGEs) releated with energy metabolism, In this study, the possible relationship between the serum levels of Advanced Glycation End Products (AGEs) of endometriosis patients and the disease and its stage is evaluated.

Arms, Groups and Cohorts

  • women with endometriosis
    • It consists of women between the ages of 18-45 who have been diagnosed with endometriosis by surgery or ultrasonography.
  • control
    • It consists of healthy women between the ages of 18-45

Clinical Trial Outcome Measures

Primary Measures

  • Serum Advanced Glycation End Products (AGEs) levels in women with endometriosis
    • Time Frame: 8 months
    • Serum Serum Advanced Glycation End Products (AGEs) levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group

Secondary Measures

  • Comparison of the relationship between serum Serum Advanced Glycation End Products (AGEs) level and endometriosis stage
    • Time Frame: 8 months
    • By comparing the relation of serum Advanced Glycation End Products (AGEs) level with the stage of endometriosis, its relation with serum level in patients with advanced and early stage endometriosis will be examined. The possible effect of Advanced Glycation End Products (AGEs) on disease pathogenesis will be examined.

Participating in This Clinical Trial

Inclusion Criteria

  • diagnosed with endometriosis (Surgery or ultrasound) – Women without endometriosis Exclusion Criteria:

  • Women without endometriosis women who are only suspected endometriosis

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Kanuni Sultan Suleyman Training and Research Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Pınar Yalcin bahat, Principal Investigator – Kanuni Sultan Suleyman Training and Research Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.